Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

E-ISSN： 1349-7006|106|11|1590-1595

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.11, 2015-11, pp. : 1590-1595

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preclinical activity of the novel B‐cell‐specific Moloney murine leukemia virus integration site 1 inhibitor PTC‐209 in acute myeloid leukemia: Implications for leukemia therapy

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1705-1713

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 611-617

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors

Cancer Science, Vol. 109, Iss. 1, 2018-01 ,pp. : 193-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression profile analysis of long non‐coding RNA in acute myeloid leukemia by microarray and bioinformatics

Cancer Science, Vol. 109, Iss. 2, 2018-02 ,pp. : 340-353

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 896-901

John Wiley & Sons Inc

Access to resources Recommend Favorite